224 related articles for article (PubMed ID: 12788824)
1. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
2. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
4. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
[TBL] [Abstract][Full Text] [Related]
7. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
9. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium.
Minotti G; Recalcati S; Mordente A; Liberi G; Calafiore AM; Mancuso C; Preziosi P; Cairo G
FASEB J; 1998 May; 12(7):541-52. PubMed ID: 9576481
[TBL] [Abstract][Full Text] [Related]
10. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
11. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat.
Cirillo R; Sacco G; Venturella S; Brightwell J; Giachetti A; Manzini S
J Cardiovasc Pharmacol; 2000 Jan; 35(1):100-8. PubMed ID: 10630739
[TBL] [Abstract][Full Text] [Related]
12. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
13. Chalcone inhibition of anthracycline secondary alcohol metabolite formation in rabbit and human heart cytosol.
Silvestrini A; Meucci E; Vitali A; Giardina B; Mordente A
Chem Res Toxicol; 2006 Nov; 19(11):1518-24. PubMed ID: 17112240
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
Licata S; Saponiero A; Mordente A; Minotti G
Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats.
Zeng X; Cai H; Yang J; Qiu H; Cheng Y; Liu M
Biomed Pharmacother; 2019 Aug; 116():108964. PubMed ID: 31102935
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
17. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent.
Hopewel JW; Duncan R; Wilding D; Chakrabarti K
Hum Exp Toxicol; 2001 Sep; 20(9):461-70. PubMed ID: 11776408
[TBL] [Abstract][Full Text] [Related]
19. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.
Salvatorelli E; Menna P; Chello M; Covino E; Minotti G
J Pharmacol Exp Ther; 2018 Feb; 364(2):323-331. PubMed ID: 29222131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
